仁度生物: 投资者关系活动记录表（2025年6月11日）

Company Overview - The company is a life sciences enterprise with an international perspective and innovative capabilities, focusing on RNA molecular diagnostics since its establishment in 2007 [2] - It has developed an integrated business model combining core raw materials, enzymes, reagents, instruments, and third-party testing services for precise pathogen diagnosis and personalized treatment across various fields [2] Product Offerings - The company offers a range of reagent products, including reproductive, respiratory, intestinal virus, and blood-borne infectious disease series, with instruments compatible with all its reagent products [2] - The respiratory series includes the first domestic product for detecting tuberculosis RNA, which is recognized for its clinical relevance and ability to detect live bacteria [2] - The reproductive series allows for non-invasive urine sample testing, providing significant convenience for patients [2] - The blood-borne infectious disease series features HBV RNA, which is the first of its kind globally, providing critical insights into liver virus activity and treatment monitoring [2] International Expansion - The company is actively pursuing international market access and has achieved milestones in Turkey with successful registrations for HPV, TB, and automated instruments [3] - It is expanding its international presence in regions such as India, Indonesia, and the Middle East, enhancing brand influence and academic reputation through participation in international exhibitions [4] Shareholder Engagement - The company emphasizes maintaining shareholder interests and adheres to a stable dividend policy, focusing on developing innovative diagnostic technologies to meet clinical needs [4] - It aims to enhance investor satisfaction by considering industry characteristics, overall business conditions, and future funding requirements in its profit distribution strategy [4]